Négociation Celularity Inc. - CELU CFD

Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic T cell therapies. It operates through Cell Therapy, Degenerative Disease, and BioBanking. Its lead therapeutic programs include CYCART-19, an allogeneic CAR-T therapy, which is in pre-clinical stage for the treatment of B-cell malignancies; CYNK-001, an allogeneic unmodified natural killer (NK) cell that is in Phase 1 clinical trial to treat acute myeloid leukemia, as well as in Phase 1/2a clinical trial for the treatment of glioblastoma multiforme and COVID-19; CYNK-101, an allogeneic genetically modified NK cell to treat HER2+ gastric cancer; and APPL-001, a placenta-derived mesenchymal-like adherent stromal cell for the treatment of crohn''s disease. The company also sells and licenses products used in surgical and wound care markets, such as Biovance and Interfyl; and collects stem cells from umbilical cords and placentas and provides cells storage under the LifebankUSA brand. Celularity Inc. was incorporated in 2016 and is based in Florham Park, New Jersey.